Pharming Group reported full-year 2024 revenues of $297 million, marking a 21% increase over 2023 and exceeding its guidance range. This growth was driven by strong performance across its commercial products.
RUCONEST contributed $252 million in revenue, an 11% increase, while Joenja generated $45 million, representing a significant 147% increase. The company also achieved operating profit in the last two quarters of 2024, signaling improving profitability.
The company's financial outlook for 2025 is positive, reflecting continued momentum from its commercial assets and strategic initiatives. This strong performance and outlook are key indicators for investors evaluating Pharming's trajectory.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.